Browsing Tag
CLIA waiver
1 post
Lumos Diagnostics (ASX: LDX) reaches 500-patient milestone in FebriDx CLIA study
Lumos Diagnostics hits a key 500-patient milestone in its FebriDx CLIA waiver study, triggering BARDA funds. FDA application expected by October 2025.